Top

Published in:

Open Access 01-12-2020 | Original research

Disease activity and response to therapy monitored by [¹⁸F]FDG PET/CT using volume-based indices in IgG4-related disease

Authors: Katsuya Mitamura, Hanae Arai-Okuda, Yuka Yamamoto, Takashi Norikane, Yasukage Takami, Kengo Fujimoto, Risa Wakiya, Hiroki Ozaki, Hiroaki Dobashi, Yoshihiro Nishiyama

Published in: EJNMMI Research | Issue 1/2020

Abstract

Purpose

The efficiency of [¹⁸F]FDG PET/CT using volume-based indices was evaluated to assess the disease activity and response to therapy in patients with immunoglobulin G4-related disease (IgG4-RD).

Methods

A total of 17 patients with IgG4-RD were examined with [¹⁸F]FDG PET/CT before and during treatment. The lesion boundary was determined using a fixed threshold of standardized uptake value (SUV) ≥ 2.5. The highest maximum SUV (SUVmax) among all affected lesions was calculated for individual patients. We summed metabolic tumor volume (MTV) and total lesion glycolysis (TLG) of each affected lesion to generate a total MTV and total TLG. PET results were compared with those of serum IgG4 and soluble interleukin-2 receptor (sIL-2R) levels.

Results

The mean number of involved organs per patient was 3.8 as determined by [¹⁸F]FDG uptake. The number of involved organs, total MTV and total TLG were significantly correlated with IgG4 (P = 0.046, < 0.001, < 0.001, respectively) and sIL-2R (P < 0.001, = 0.031, 0.031, respectively). According to the clinical assessments for therapy response, all patients were classified as improved. The SUVmax, total MTV, and total TLG during therapy were all significantly lower than those before therapy (all P < 0.001).

Conclusion

[¹⁸F]FDG PET/CT is valuable for assessing the extent of multi-organ involvement before therapy and monitoring subsequent therapy in patients with IgG4-RD. [¹⁸F]FDG PET/CT using volumetric indices correlated with serum IgG4 and sIL-2R levels.

Khosroshahi A, Stone JH. A clinical overview of IgG4-related systemic disease. Curr Opin Rheumatol. 2011;23:57–66.CrossRef

Kamisawa T, Zen Y, Pillai S, Stone JH. IgG4-related disease. Lancet. 2015;385:1460–71.CrossRef

Wallace ZS, Naden RP, Chari S, Choi H, Della-Torre E, Dicaire JF, et al. The 2019 American College of Rheumatology/European League Against Rheumatism Classification Criteria for IgG4-related disease. Arthritis Rheumatol. 2020;72:7–19.CrossRef

Gotthardt M, Bleeker-Rovers CP, Boerman OC, Oyen WJ. Imaging of inflammation by PET, conventional scintigraphy, and other imaging techniques. J Nucl Med. 2010;51:1937–49.PubMed

Vaidyanathan S, Patel CN, Scarsbrook AF, Chowdhury FU. FDG PET/CT in infection and inflammation–current and emerging clinical applications. Clin Radiol. 2015;70:787–800.CrossRef

Nakajo M, Jinnouchi S, Fukukura Y, Tanabe H, Tateno R, Nakajo M. The efficacy of whole-body FDG-PET or PET/CT for autoimmune pancreatitis and associated extrapancreatic autoimmune lesions. Eur J Nucl Med Mol Imaging. 2007;34:2088–95.CrossRef

Matsubayashi H, Furukawa H, Maeda A, Matsunaga K, Kanemoto H, Uesaka K, et al. Usefulness of positron emission tomography in the evaluation of distribution and activity of systemic lesions associated with autoimmune pancreatitis. Pancreatology. 2009;9:694–9.CrossRef

Nakatani K, Nakamoto Y, Togashi K. Utility of FDG PET/CT in IgG4-related systemic disease. Clin Radiol. 2012;67:297–305.CrossRef

Ebbo M, Grados A, Guedj E, Gobert D, Colavolpe C, Zaidan M, et al. Usefulness of 2-[¹⁸F]-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography for staging and evaluation of treatment response in IgG4-related Disease: a retrospective multicenter study. Arthritis Care Res. 2014;66:86–96.CrossRef

10.

Nakatsuka Y, Handa T, Nakamoto Y, Nobashi T, Yoshihuji H, Tanizawa K, et al. Total lesion glycolysis as an IgG4-related disease activity marker. Mod Rheumatol. 2015;25:579–84.CrossRef

11.

Zhang J, Chen H, Ma Y, Xiao Y, Niu N, Lin W, et al. Characterizing IgG4-related disease with ¹⁸F-FDG PET/CT: a prospective cohort study. Eur J Nucl Med Mol Imaging. 2014;41:1624–34.CrossRef

12.

Takahashi H, Yamashita H, Morooka M, Kubota K, Takahashi Y, Kaneko H, et al. The utility of FDG-PET/CT and other imaging techniques in the evaluation of IgG4-related disease. Joint Bone Spine. 2014;81:331–6.CrossRef

13.

Yabusaki S, Oyama-Manabe N, Manabe O, Hirata K, Kato F, Miyamoto N, et al. Characteristics of immunoglobulin G4-related aortitis/periaortitis and periarteritis on fluorodeoxyglucose positron emission tomography/computed tomography co-registered with contrast-enhanced computed tomography. EJNMMI Res. 2017;7:20.CrossRef

14.

Larson SM, Erdi Y, Akhurst T, Mazumdar M, Macapinlac HA, Finn RD, et al. Tumor treatment response based on visual and quantitative changes in global tumor gycolysis uing PET-FDG imaging. The viual response score and the change in total lesion glycolysis. Clin Positron Imaging. 1999;2:159–171.

15.

Hirata K, Kobayashi K, Wong KP, Manabe O, Surmak A, Tamaki N, et al. A semi-automated technique determining the liver standardized uptake value reference for tumor delineation in FDG PET-CT. PLoS ONE. 2014;9:e105682.CrossRef

16.

Khosroshahi A, Carruthers MN, Deshpande V, Unizony S, Bloch DB, Stone JH. Rituximab for the treatment of IgG4-related disease. Medicine. 2012;91:57–66.CrossRef

17.

Shimizu Y, Yamamoto M, Naishiro Y, Sudoh G, Ishigami K, Yajima H, et al. Necessity of early intervention for IgG4-related disease–delayed treatment induces fibrosis progression. Rheumatology (Oxford). 2013;52:679–83.CrossRef

18.

Tabata T, Kamisawa T, Takuma K, Egawa N, Setoguchi K, Tsuruta K, et al. Serial changes of elevated serum IgG4 levels in IgG4-related systemic disease. Intern Med. 2011;50:69–75.CrossRef

19.

Umehara H, Okazaki K, Masaki Y, Kawano M, Yamamoto M, Aseki T, et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol. 2012;22:21–30.CrossRef

20.

Okazaki K, Uchida K, Koyabu M, Miyoshi H, Takaoka M. Recent advances in the concept and diagnosis of autoimmune pancreatitis and IgG4-related disease. J Gastroenterol. 2011;46:277–88.CrossRef

21.

Yamamoto M, Takahashi H, Tabeya T, Suzuki C, Naishiro Y, Ishigami K, et al. Risk of malignancies in IgG4-related disease. Mod Rheumatol. 2012;22:414–8.CrossRef

Title: Disease activity and response to therapy monitored by [18F]FDG PET/CT using volume-based indices in IgG4-related disease
Authors: Katsuya Mitamura
Hanae Arai-Okuda
Yuka Yamamoto
Takashi Norikane
Yasukage Takami
Kengo Fujimoto
Risa Wakiya
Hiroki Ozaki
Hiroaki Dobashi
Yoshihiro Nishiyama
Publication date: 01-12-2020
Publisher: Springer Berlin Heidelberg
Published in: EJNMMI Research / Issue 1/2020
Electronic ISSN: 2191-219X
DOI: https://doi.org/10.1186/s13550-020-00743-w

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Disease activity and response to therapy monitored by [¹⁸F]FDG PET/CT using volume-based indices in IgG4-related disease

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2020

Diagnostic value of PET/CT with 11C-methionine (MET) and 18F-fluorothymidine (FLT) in newly diagnosed glioma based on the 2016 WHO classification

Gallium-68 prostate-specific membrane antigen ([68Ga]Ga-PSMA-11) PET for imaging of thyroid cancer: a feasibility study

Convolutional neural networks for improving image quality with noisy PET data

Selective serotonin reuptake inhibitors (SSRIs) prevent meta-iodobenzylguanidine (MIBG) uptake in platelets without affecting neuroblastoma tumor uptake

A pan-cancer analysis of the clinical and genetic portraits of somatostatin receptor expressing tumor as a potential target of peptide receptor imaging and therapy

Neuron-specific enolase has potential value as a biomarker for [18F]FDG/[68Ga]Ga-PSMA-11 PET mismatch findings in advanced mCRPC patients